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Abstract
Constitutive activation of STAT3 is a common feature in many solid tumors including non-small cell lung carcinoma (NSCLC).
While activation of STAT3 is commonly achieved by somatic mutations to JAK2 in hematologic malignancies, similar
mutations are not often found in solid tumors. Previous work has instead suggested that STAT3 activation in solid tumors is
more commonly induced by hyperactive growth factor receptors or autocrine cytokine signaling. The interplay between
STAT3 activation and other well-characterized oncogenic ‘‘driver’’ mutations in NSCLC has not been fully characterized,
though constitutive STAT3 activation has been proposed to play an important role in resistance to various small-molecule
therapies that target these oncogenes. In this study we demonstrate that STAT3 is constitutively activated in human NSCLC
samples and in a variety of NSCLC lines independent of activating KRAS or tyrosine kinase mutations. We further show that
genetic or pharmacologic inhibition of the gp130/JAK2 signaling pathway disrupts activation of STAT3. Interestingly,
treatment of NSCLC cells with the JAK1/2 inhibitor ruxolitinib has no effect on cell proliferation and viability in two-
dimensional culture, but inhibits growth in soft agar and xenograft assays. These data demonstrate that JAK2/STAT3
signaling operates independent of known driver mutations in NSCLC and plays critical roles in tumor cell behavior that may
not be effectively inhibited by drugs that selectively target these driver mutations.
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Introduction
Non-small cell lung carcinoma (NSCLC) is characterized by a
remarkable variety of genomic alterations and point mutations
that collectively disrupt the normal molecular programs which
regulate growth and survival of the lung epithelium [1,2]. Despite
the genomic complexity of individual lung tumors, however, it
appears that most oncogenic programs are driven by only a few
key mutations, which are required to maintain the viability and
proliferation of tumor cells. The key ‘‘driver oncogenes’’ that have
been associated with NSCLC include Kirsten rat sarcoma viral
oncogene homolog (KRAS) and several receptor tyrosine kinases
(RTK) such as the epidermal growth factor receptor (EGFR),
platelet-derived growth factor receptor (PDGFR), anaplastic
lymphoma kinase (ALK) and hepatocyte growth factor receptor
(HGFR/MET) [3]. All of these oncogenes converge upon a
number of signaling pathways that have been recurrently
implicated across the spectrum of solid tumors.
While effective treatments for KRAS-driven tumors have
generally been lacking, significant progress has been made in the
development of tyrosine kinase inhibitors (TKI) that selectively
block the activity of constitutively activated RTKs [4]. Perhaps the
best example of this therapeutic strategy is the development of
small-molecule inhibitors of EGFR, including gefitinib and
erlotinib [5,6]. Patients with specific activating mutations to
EGFR respond favorably to these drugs, though most eventually
relapse or progress due to a variety of acquired resistance
mechanisms [7]. Recent work in several different cancer types
has indicated a particular role for the microenvironment—
including both stromal and inflammatory cells—in acquired drug
resistance, though the specific signaling mechanisms associated
with this process remain incompletely understood [4,8,9].
Of the many different microenvironment signaling cues that
contribute to tumor cell survival, those that induce the activation
of signal transducer and activator of transcription (STAT) family
proteins appear to be particularly important in tumor drug
resistance [10,11]. STAT3, which can be activated by a variety of
growth factor and inflammatory signals from the microenviron-
ment, has been implicated in both primary and acquired resistance
to chemotherapy [12,13,14]. In addition, STAT3 was recently
identified as a target in a large-scale synthetic lethal screen
designed to isolate compounds that synergize with EGFR
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STAT3 is required for efficient cellular transformation by an array
of well-characterized oncogenes including Ras, v-Src, SV40 T-
antigen, and EGFR, further validating the importance of STAT3
in cancer biology [16,17,18,19,20].
STAT3 is primarily activated by tyrosine (Y705) phosphoryla-
tion, which can be mediated by a number of tyrosine kinases
included those of the SRC and JAK families [10,21]. Tyrosine-
phosphorylated STAT3 molecules form homodimers that traffic to
the nucleus, bind DNA and activate transcription of key target
genes involved in cellular proliferation, survival and migration.
While other phosphorylation-independent functions have been
described for STAT3, it is unclear whether they play an important
role in the pro-oncogenic function of STAT3 in human tumors
[22]. Conversely, many studies have demonstrated the importance
of tyrosine-phosphorylation in the oncogenicity of STAT3,
suggesting that this modification is critical for its role in cellular
transformation [10,21]. Notably, tyrosine-phosphorylated STAT3
has been found in up to 50% of late-stage NSCLC, suggesting a
possible role in the etiology or progression of this cancer
[10,23,24].
In this study we sought to identify signaling pathways that
remain active after treatment of NSCLC lines with TKIs. Our
data demonstrate that STAT3 activity is unaffected by TKI
treatment in several different cellular contexts. Furthermore, we
show that STAT3 phosphorylation at Y705 is primarily regulated
by the gp130/JAK2 signaling complex, and is constitutively active
in several different NSCLC cell lines as well as in 22% of early-
stage NSCLC samples. Treatment of NSCLC lines with the JAK2
inhibitor ruxolitinib inhibits anchorage independent growth and
slows xenograft tumor formation, suggesting that selected patients
with NSCLC may benefit from treatment with JAK2 inhibitors in
addition to TKI.
Results
Targeted Kinase Inhibitors Fail to Downregulate STAT3
Phosphorylation
In order to identify signaling pathways that fail to respond to
targeted tyrosine kinase inhibitors (TKIs), we treated EGFR-
mutant cell lines (HCC827 and HCC4006) with the small
molecule inhibitor erlotinib and assayed multiple signaling
pathways using a phosphoprotein array (Fig. 1A–B). As expected,
both EGFR and several of its downstream effectors—including PI-
3-kinase (PI3K), mTOR and ERK—are deactivated by erlotinib
treatment. However, we also observed that STAT3 remains
activated in both cell lines after erlotinib treatment (Fig. 1A–B,
array location 10). Immunoblot analysis of these pathways
confirmed the findings of the phosphoprotein array, suggesting
that STAT3 is activated independent of EGFR in these NSCLC
cells (Fig. 1C). Furthermore, inhibition of EGFR with erlotinib
failed to change the nuclear localization of STAT3 in HCC4006
cells, indicating that STAT3 remains active and appropriately
localized in the absence of signaling by EGFR (Fig. 1D)
To extend these findings, we analyzed activation of STAT3 in
five other NSCLC lines with diverse ‘‘driver oncogenes’’
commonly found in non-squamous NSCLC (Table S1). Treat-
ment of KRAS mutant cells (A549, NCI-H358, NCI-H460) with
the MEK1/2 inhibitor U0126 readily inhibits activation of the
MAPK pathway (ERK1/2), but fails to inhibit STAT3 activation
(Fig. 2A). In fact, we observed that MEK1/2 inhibition actually
increases STAT3 phosphorylation, suggesting that STAT3 may be
activated in response to a decrease in MEK activity downstream of
KRAS signaling (Fig. 2A) [25].
We also analyzed the activation of STAT3 in NSCLC lines
bearing genomic amplification of the tyrosine kinases PDGFRA
(NCI-H1703) and MET (NCI-H1993), both of which are found to
be amplified or mutated in NSCLC [26,27]. Inhibition of
PDGFRA with the TKI sunitinib and MET with the TKI
crizotinib potently blocks the activation of PI3K, RAS and mTOR
pathways, as demonstrated by decreased phosphorylation of the
downstream effector proteins AKT, ERK1/2 and S6 in both cell
lines (Fig. 2B–C). Even at relatively high doses, however, neither
sunitinib nor crizotinib significantly decreases the phosphorylation
of STAT3 compared to these other RTK signaling effectors.
To demonstrate that STAT3 activation in each of the seven
NSCLC lines occurs independent of serum stimulation, we plated
cells at a fixed density, allowed them to adhere overnight and then
treated them with or without fetal bovine serum (FBS, 10%) for
24 hours. Immunoblot analysis of signaling protein phosphoryla-
tion in these conditions indicates that activation of AKT, ERK1/2
and S6 is variably dependent upon serum stimulation, depending
on cell type, while STAT3 activation occurs independent of serum
stimulation (Fig. 2D). These data collectively suggest that STAT3
is activated independent of growth factor signaling pathways or
activated RTKs in NSCLC, and is therefore insensitive to kinase
inhibitors that target these pathways.
STAT3 is Activated via Autocrine Signaling by IL-6 Family
Ligands
Previous studies have suggested that STAT3 is primarily
activated in autocrine fashion by the interleukin-6 (IL-6) family of
cytokines in NSCLC [14,24]. These cytokines all bind and activate
the common co-receptor gp130, which can be blocked using
neutralizing antibodies that prohibit binding of all IL-6 superfamily
cytokines to the extracellular region of the receptor. We found that
gp130 neutralization effectively decreases STAT3 phosphorylation
in all seven NSCLC lines regardless of their driver mutation status,
suggesting that one or more IL-6 family ligands is responsible for
autocrine activation of STAT3 in these cell lines (Fig. 3A).
The IL-6 family of cytokines contains seven different members,
though only IL-6 itself has been previously implicated in NSCLC
[14,24]. To determine whether IL-6 was expressed in the seven
NSCLC lines, we measured the production of IL-6 and several
other inflammatory cytokines in conditioned media after 48 hours
of culture in serum-free conditions (Table S2). Of the seven
NSCLC lines tested, however, only three (NCI-H460, HCC827
and HCC4006) produce appreciable levels of IL-6 relative to
normal human serum (Fig. 3B). These findings are consistent with
mRNA expression data, which demonstrate that the four NSCLC
lines lacking detectable production of IL-6 ligand (A549, NCI-
H358, NCI-H1703 and NCI-H1993) also fail to express IL-6
mRNA (Fig S1A).
At this time it is unclear which other IL-6 family ligand is
responsible for STAT3 activation in the four cell lines that lack
detectlable IL-6 expression. Ofthe seven IL-6 family ligands present
in the human genome, only cardiotrophin-like cytokine factor 1
(CLCF1) is expressed at levels similar to or above IL-6 in the
NSCLC lines we testedby quantitative RT-PCR(Fig S1A). Because
commercial tests for CLCF1 are not available, we developed a
sandwich ELISA for CLCF1 that can quantify soluble ligand in
serum-free tissue culture media (Fig S1B). Using this assay we were
able to detect CLCF1 in the conditioned media of several of the
NSCLC lines (Fig S1C). The significance of this finding is unclear,
however, since lung epithelial cells lack the primary receptor for this
ligand (ciliary neurotrophic factor receptor, CNTFR) and fail to
respond to recombinant CLCF1 (Fig S1D). Further studies will be
required to accurately measure secretion of other IL-6 family
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STAT3 via the gp130 receptor in NSCLC.
STAT3 is Primarily Activated by JAK2 in NSCLC
Inflammatory cytokines that signal through gp130 primarily
activateSTATproteinsvianon-receptortyrosinekinasesoftheJAK
family. This kinase family is composed of four members: JAK1,
JAK2,JAK3and Tyk2.Ofthese,onlyJAK2iscommonlyexpressed
in cells of the epithelial lineage from which NSCLC arises [10,28].
To test whether STAT3 is phosphorylated by JAK2, we treated the
seven different NSCLC lines with the small molecule inhibitor
ruxolitinib, which selectively targets both JAK1 and JAK2. Dose-
response (Fig. 4A) and timecourse treatment (Fig. 4B) with
ruxolitinib results in a rapid loss of STAT
Y705 phosphorylation in
all but one (NCI-H1993; not shown) of the NSCLC lines tested.
Importantly, this drug had little to no effect on any other signaling
pathwayswetested,demonstratingitsspecificityfortheJAK/STAT
pathway relative to other mitogenic signaling cascades.
To further confirm that JAK2—and not JAK1—is responsible
for STAT3
Y705 phosphorylation in NSCLC, we used lentiviral
Figure 1. Erlotinib fails to inhibit STAT3 activation in EGFR mutant NSCLC cell lines. A–B, Protein lysates from HCC827 (A) and HCC4006
(B) cells treated with DMSO (vehicle) or 2 mM erlotinib for 8 hours were analyzed with antibody microarrays to detect phosphorylation status of
receptor tyrosine kinases and key cell signaling proteins. Fluorescent signals for the indicated spots were background subtracted and normalized to
positive control spots (indicated with +) on the array. Data is shown as the percentage of average fluorescence for each set of duplicate spots relative
to the average fluorescence of ten positive control spots for each array. Data on each graph is ordered according to the number (1–10) indicated on
each array. C, HCC827 and HCC4006 cells were treated for one hour with DMSO (con) or a 2-fold escalating dose of erlotinib ranging from 0.25 to
1.0 mM (left-right). The phosphorylation status of EGFR (pEGFR
Y1068), STAT3 (pSTAT3
Y705), AKT (pAKT
S473), ERK (pERK
T202/Y204), and S6 (pS6
S235/S236)
was evaluated by immunoblot. Equal amounts of protein (20 mg) were added for each sample. D, HCC4006 cells were treated for two hours with
DMSO or 1.0 mM erlotinib, then fixed and stained with antibodies for total STAT3. Cells were counter-stained with DAPI to indicate nuclear
accumulation of STAT3. Scale bars, 20 mm.
doi:10.1371/journal.pone.0030820.g001
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Depletion of JAK2 in NCI-H1703 cells—which demonstrate the
highest levels of STAT3 and pSTAT3
Y705 expression—results in a
near complete loss of STAT3 phosphorylation comparable to
ruxolitinib, supporting the hypothesis that JAK2 is the kinase
primarily responsible for STAT3
Y705 phosphorylation in NSCLC
(Fig. 4C).
JAK2 Expression Coincides with STAT3 Phosphorylation
in Human NSCLC Samples
To address the importance of JAK2/STAT3 signaling in
human tumor tissue samples, we performed immunohistochemis-
try (IHC) for JAK2, STAT3 and pSTAT3
Y705 on a clinically
annotated tissue microarray (Table S3) containing 245 stage I/II
NSCLC samples (Fig. 4D). In the NSCLC samples analyzed,
KRAS and EGFR mutations were present in 26.0% and 5.6% of
patients, respectively.
The majority of tumors display positive staining for STAT3
(94%) and JAK2 (79%), while a smaller percentage display positive
staining for pSTAT3
Y705 (22%) (Fig. 4E). Importantly, all but one
of the tumors that were scored as pSTAT3
Y705 positive (n=53)
also scored positive for JAK2. Furthermore, staining for
pSTAT3
Y705 was positively correlated with the intensity of
JAK2 staining (Pearson correlation coefficient 0.32; 95% Confi-
dence Interval (CI) 0.20–0.43; p=3.65610
207), consistent with a
key role for JAK2 in STAT3 activation. As would be expected for
specific total/phospho-specific antibody pairs, positive
pSTAT3
Y705 staining was also positively correlated with the
intensity of total STAT3 staining (Pearson correlation coefficient
0.37; 95% CI 0.25–0.47; p=2.59610
209).
We found no statistically significant correlations between
histology, age and gender with the IHC staining or KRAS/
EGFR mutational status, though KRAS mutational status was
positively correlated with adenocarcinoma histology, similar to
previous reports (Pearson chi-squared 12.38; p-value=2.04610
203)
[29]. In addition, there were no significant correlations between
KRAS or EGFR mutational status and IHC staining for any of the
three proteins, nor were any of the IHC staining patterns
significantly associated with relapse-free (RFS) or overall survival
(OS). In line with the LACE (Lung Adjuvant Cisplatin Evaluation)
meta-analysis, we found no significant correlation between EGFR
or KRAS mutation status with RFS and OS [30]. The lack of
correlation between prominent oncogenic mutations and STAT3
activation in human lung tumor samples further supports our in
vitro finding that STAT3 phosphorylation is independent of key
driver oncogenes, and is more likely an indicator of autocrine or
stromal production of pro-inflammatory cytokines.
JAK2 Inhibition Fails to Enhance Toxicity of Targeted
Kinase Inhibitors
Because ruxolitinib and the targeted kinase inhibitors we tested
appear to target distinct signaling pathways, we combined these
agents together to achieve inhibition of both sets of effector
proteins in each pathway. Combination of ruxolitinib with U0126,
erlotinib or sunitinib effectively inhibited signaling to STAT3,
AKT, ERK and S6, indicating that the JAK2, PI3K, MEK and
mTOR pathways can be inhibited together using combinatorial
drug treatment (Fig. 5A,C,E). To determine whether treatment
with ruxolitinib enhances the efficacy of targeted kinase inhibitors
in vitro, we treated three of the NSCLC lines with a three-fold serial
dilution of their matched TKI in the presence or absence of 1 mM
ruxolitinib. We found that ruxolitinib has little effect on the
efficacy of any of these inhibitors in 24 hour viability (Fig. 5B,D,F)
or 72 hour proliferation assays (Fig S2) in two-dimensional culture.
Similarly, treatment of each of these cell lines with a three-fold
serial dilution of ruxolitinib alone had no effect on cell viability or
proliferation, even at doses that completely inhibit STAT3
phosphorylation (data not shown).
JAK2/STAT3 Signaling Mediates Growth of NSCLC Cells in
Soft Agar and In Vivo
Similar results to those described above were recently obtained
in RAS-transformed MCF10A cells, which do not require STAT3
for survival or proliferation in the context of two-dimensional
tissue culture, but do require STAT3 for anchorage-independent
Figure 2. Targeted kinase inhibitors fail to downregulate
STAT3 phosphorylation in NSCLC cell lines with diverse driver
mutations. A, KRAS mutant NSCLC cell lines (A549, NCI-H358 and NCI-
H460) were treated for one hour with DMSO (con) or a 2-fold escalating
dose of the MEK1/2 inhibitor U0126 ranging from 0.625 to 5.0 mM (left-
right). The phosphorylation status of STAT3 (pSTAT3
Y705), AKT
(pAKT
S473), ERK (pERK
T202/Y204), and S6 (pS6
S235/S236) was evaluated by
immunoblot. Equal amounts of protein (20 mg) were added for each
sample. B, PDGFRA amplified/mutant NSCLC cells (NCI-H1703) were
treated for one hour with DMSO (con) or a 2-fold escalating dose of the
PDGFRA inhibitor sunitinib ranging from 0.625 to 2.5 mM (left-right).
Phospho-protein status was evaluated in 20 mg of protein per sample as
in A. C, MET amplified NSCLC cells (NCI-H1993) were treated for one
hour with DMSO (con) or a 2-fold escalating dose of the MET/ALK
inhibitor crizotinib ranging from 0.25 to 1.0 mM (left-right). Phospho-
protein status was evaluated in 20 mg of protein per sample as in A. D,
The indicated NSCLC lines were plated at fixed densities and allowed to
adhere for 24 hours. Cells were then treated for 18 hours in normal
media with (+) or without (2) 10% fetal bovine serum (FBS). Phospho-
protein status was evaluated in 20 mg of protein per sample as in A.
Even sample loading is indicated by replicate immunoblot for beta-
tubulin.
doi:10.1371/journal.pone.0030820.g002
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required for growth of NSCLC lines in three-dimensional culture,
we performed soft agar colony formation assays on each of the
seven NSCLC in the presence of vehicle only (DMSO) or
ruxolitinib (2 mM). Four of the seven lines we tested display
anchorage independent growth by forming individual colonies in
soft agar (A549, HCC827, NCI-H1703, NCI-H460). Continuous
treatment of these cell lines with ruxolitinib decreases both the
efficiency of colony formation (Fig. 6A) and the average size of
colonies (Fig. 6B) in three of the four lines, indicating that JAK2/
STAT3 signaling is important for anchorage-independent growth
of specific subsets of NSCLC. The effect of ruxolitinib was
particularly dramatic in NCI-H1703 cells, which failed to form
any colonies at all in the presence of ruxolitinib. Notably, this cell
line has the highest basal level of STAT3 phosphorylation of all
the cell lines we tested (Fig. 2, 3).
To further validate the effect of JAK2 inhibition on tumor
growth in vivo, we performed xenograft assays with HCC-827 lung
adenocarcinoma cells, which are driven by an activating mutation
(E746-A750 deletion) in EGFR [31]. We injected 5610
6 cells into
Figure 3. STAT3 phosphorylation is mediated by IL-6 family cytokines in NSCLC cell lines. A, The indicated NSCLC lines were plated at
fixed densities and allowed to adhere overnight in serum-containing media. Cells were then treated for 24 hours in serum-free media containing anti-
gp130 neutralizing antibody or a control mouse IgG (2.0 mg/mL each). Protein lysates were harvested and the phosphorylation status of STAT3
(pSTAT3
Y705), AKT (pAKT
S473), ERK (pERK
T202/Y204), and S6 (pS6
S235/S236) was evaluated by immunoblot. Equal amounts of protein (30 mg) were added
for each sample. B, NSCLC lines were plated at fixed densities and allowed to adhere overnight in serum-containing media. Cells were then serum-
starved, and conditioned media was collected at 48 hours. Secreted interleukin-6 (IL-6) levels were measured from the indicated cell lines using a
bead-based immunoassay platform. Values shown are averages of duplicate measurements for each sample.
doi:10.1371/journal.pone.0030820.g003
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volume of 100 mm
3. The mice were then separated into two groups
of six mice each and treated daily with vehicle (0.5% hydro-
xypropylmethylcellulose/0.2% Tween 80 in PBS) or ruxolitinib
(50 mg/kg) by oral gavage. We found that ruxolitinib treatment
slowed tumor growth in vivo, decreasing tumor volume by 36%
(vehicle, 549.66260.2 mm
3 vs. ruxolitinib, 352.86103.7 mm
3)
over 30 days of treatment (Fig. 6C). These data are consistent with
the soft agar growth assays, and confirm the importance of JAK2/
STAT3 signaling in the growth of NSCLC tumors.
Figure 4. STAT3 phosphorylation is mediated by the tyrosine kinase JAK2 in NSCLC. A, The indicated NSCLC lines were plated at a fixed
density and allowed to adhere overnight. Cells were then treated for 16 hours with DMSO (con) or a 2-fold escalating dose of the JAK1/2 inhibitor
ruxolitinib ranging from 0.25 to 4.0 mM (left-right). Protein lysates were harvested and the phosphorylation status of STAT3 (pSTAT3
Y705), AKT
(pAKT
S473), ERK (pERK
T202/Y204), and S6 (pS6
S235/S236) was evaluated by immunoblot. Equal amounts of protein (20 mg) were added for each sample. B,
The same NSCLC lines were plated as in A, but were treated with a fixed dose of ruxolitinib (1 mM) for the indicated time. Phospho-protein status was
evaluated in 20 mg of protein per sample as in A. C, NCI-H1703 cells were infected with lentiviral vectors containing a control shRNA (NT, non-
targeting) or one of two shRNAs targeted to human JAK2 (sh1 or sh2). Protein lysates were harvested and evaluated for JAK2 expression and STAT3
phosphorylation by immunoblot. Blots for total STAT3 and tubulin were included to demonstrate equal loading. D, Representative images of
immunohistochemical stains for total JAK2, total STAT3 and phosphorylated STAT3 (pSTAT3
Y705) performed on a tissue microarray containing 245
pathologically verified human NSCLC samples. Images were captured from staining performed serial sections of the same tumor samples. E,
Summary of staining results for JAK2, STAT3 and pSTAT3
Y705 on the NSCLC tissue microarray (n=245). Note that all but one of the samples with
positive nuclear pSTAT3
Y705 staining (52/53, 98.1%) were also positive for JAK2.
doi:10.1371/journal.pone.0030820.g004
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The JAK/STAT signaling pathway has long been associated
with hematologic malignancies, particularly those of the myeloid
lineage. An essential role for JAK2/STAT3 has been most clearly
identified in myeloproliferative disorders (polycythemia vera,
essential thrombocythemia, idiopathic myelofibrosis) and several
different myeloid malignancies (atypical CML, CMML, megakar-
yocytic AML, JMML), all of which bear a high proportion of
somatic JAK2 mutations (i.e. V617F) that lead to constitutive
kinase activation [32]. The strong association of JAK2 mutations
with these cancers—as well as a wealth of preclinical validation—
Figure 5. JAK2 inhibition with ruxolitinib does not affect kinase inhibitor toxicity in two-dimensional tissue culture. A, NCI-H358 cells
(KRAS mutant) were plated at fixed density and treated for 24 hours with DMSO (2), U0126 (5.0 mM), ruxolitinib (1.0 mM) or both drugs. Protein
lysates were harvested and the phosphorylation status of STAT3 (pSTAT3
Y705), AKT (pAKT
S473), ERK (pERK
T202/Y204), and S6 (pS6
S235/S236) was evaluated
by immunoblot. Equal amounts of protein (20 mg) were added for each sample. B, NCI-H358 cells were treated in quadruplicate with a 3-fold serial
dilution of the MEK1/2 inhibitor U0126 (range, 0–30 mM) +/2 1.0 mM ruxolitinib. Cell viability was measured 24 hours after treatment. Averaged
values for each condition are shown as a percentage of vehicle-treated (DMSO) cells. Error bars indicate standard deviations of the four replicate
values. C, HCC4006 cells (EGFR mutant) were plated at fixed density and treated for 24 hours with DMSO (2), erlotinib (1.0 mM), ruxolitinib (1.0 mM) or
both drugs. Protein lysates were harvested and analyzed as in A. D, HCC4006 cells were treated in quadruplicate for 24 hours with a 3-fold serial
dilution of the EGFR inhibitor erlotinib (range, 0–1.0 mM) +/2 1.0 mM ruxolitinib. Cell viability and percent survival was evaluated as in B. E, NCI-H1703
cells (PDGFR amplified/mutant) were plated at fixed density and treated for 24 hours with DMSO (2), sunitinib (1.0 mM), ruxolitinib (1.0 mM) or both
drugs. Protein lysates were harvested and analyzed as in A. F, NCI-H1703 cells were treated in quadruplicate for 24 hours with a 3-fold serial dilution
of the PDGFR inhibitor sunitinib (range, 0–100 mM) +/2 1.0 mM ruxolitinib. Cell viability and percent survival was evaluated as in B.
doi:10.1371/journal.pone.0030820.g005
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which are already in various stages of clinical testing [33]. Most
notable among these drugs is the JAK1/2 selective inhibitor
ruxolitinib (INCB018424), which has shown promising results and
relatively low toxicity in phase I/II clinical testing of patients with
primary myelofibrosis [34]. Use of this inhibitor in JAK2-
transformed cells leads to rapid dephosphorylation of STAT3
concomitant with growth arrest and death of these cells [35].
While emerging studies continue to implicate STAT3 as an
important oncogene in solid tumors, it is still unclear precisely how
STAT3 becomes activated in this context [10,11]. Phosphoryla-
tion of STAT3 at Y705 is both positively and negatively regulated
by several different mechanisms, several of which have direct
relevance to NSCLC. Negative regulators of STAT3 in particular
are common targets of mutation, silencing or deletion in NSCLC.
Direct dephosphorylation of STAT3 is achieved by the phospha-
tase PTPRD, which is commonly mutated or epigenetically
silenced in the majority of NSCLC [36]. STAT3 activity is also
regulated by a negative feedback loop involving SOCS3, a STAT3
target gene that is transcriptionally activated following STAT3
activation [37]. SOCS3 binds to activated tyrosine kinases,
thereby limiting their access to substrates including STAT3. This
effectively limits the positive input to STAT3, and allows for
effective dephosphorylation and inactivation. Notably, SOCS3 has
also been shown to be epigenetically silenced in NSCLC,
suggesting a selective role for STAT3 activation in this disease.
Positive regulators of Y705 phosphorylation include the Janus
kinase (JAK) and SRC family of non-receptor tyrosine kinases,
both of which are commonly hyperactivated in solid malignancies.
Unlike hematologic malignancies, however, activating mutations
to JAK family kinases are rarely found in epithelial-derived solid
tumors [38,39]. Instead, these kinases appear to be activated by
upstream signal transduction pathways induced by mutated
growth factor receptors or inflammatory cytokines, particularly
those of the IL-6 family [24,40,41,42,43]. The relative contribu-
tions of each of these different stimuli to STAT3 activation in
NSCLC is currently unclear, and poses an important problem for
pharmacologic management of this disease.
In this study we show that STAT3 is predominantly activated
by JAK2-dependent phosphorylation of Y705 in NSCLC lines
that are transformed by diverse driver mutations. We also
demonstrate that inhibition of MEK, EGFR, MET, or PDGFRA
is unable prevent activation of STAT3 in NSCLC, suggesting that
these hyperactive growth factor signaling pathways do not play a
major role in the constitutive activation of STAT3. As such, our
data imply that pharmacologic therapies targeting these pathways
in NSCLC are unlikely to impact STAT3 or any of the cellular
phenotypes that it transcriptionally regulates. Because STAT3
signaling has been implicated in therapeutic resistance to several
different cancer treatments, ongoing efforts to target receptor
tyrosine kinase signaling networks in NSCLC would likely be
improved by combination with ruxolitinib or other JAK family
inhibitors [14,15,44].
Previous studies have clearly implicated the cytokine IL-6 as a
key activator of JAK2 in NSCLC [14,24]. While three of the seven
cell lines we examined confirm this finding, our data also suggest
that IL-6 is not the only cytokine involved in this process. The
other four lines we analyzed fail to produce detectable levels of
soluble IL-6, but remain sensitive to gp130 neutralization,
suggesting that other IL-6 family ligands might be involved. This
finding implies that therapeutic neutralization of IL-6 itself with
humanized monoclonal antibodies—which has been developed for
other auto-inflammatory conditions—is unlikely to be as effective
as inhibiting the downstream effectors of all IL-6 family ligands,
Figure 6. JAK2 inhibition with ruxolitinib inhibits NSCLC cell
growth in soft agar and in xenograft assays. A–B, NSCLC cells
were plated into a soft-agar suspension (5,000 cells/35 mm well) and
overlaid with normal media containing 10% FBS +/2 2.0 mM ruxolitinib.
After one month, agar plugs were fixed and stained with crystal violet to
identify individual colonies. Digital images of each well were captured
and analyzed for colony number and size. Average colony formation
efficiency ([# colonies/# plated cells] 6100%, A) and mean colony size
(area in mm
2, B) for triplicate experiments are shown. Error bars indicate
the standard deviation for triplicate wells. (*, p-value,0.05). C, HCC827
cells were xenografted into the flanks of nude mice. When tumors
reached a volume of 100 mm
3, mice were separated into two treatment
arms (n=6,each)anddoseddailybyoralgavagewithvehicleor the JAK2
inhibitor ruxolitinib (50 mg/kg). Tumor size was evaluated every other
day. Animals were sacrificed when tumors reached 500 mm
3 or after one
month of treatment. Error bars indicate the standard error of tumor
volume measurements. (*, p-value,0.05).
doi:10.1371/journal.pone.0030820.g006
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such, future combinatorial approaches should focus on therapies
that target these molecules in addition to key ‘‘driver oncogenes’’
such as KRAS and EGFR.
Materials and Methods
Cell Culture
All seven NSCLC lines (HCC827, HCC4006, A549, NCI-
H358, NCI-H460, NCI-H1703, NCI-H1993) were obtained
from ATCC. Cells were grown in normal tissue culture-treated
flasks in RPMI-1640 media containing 10% fetal bovine serum
(FBS) under standard growth conditions of 5% CO2.C e l l sw e r e
passaged at 85–90% confluency every 3–4 days to maintain
continuous logarithmic growth. Drug treatments with erlotinib
(LC Labs, Woburn, MA), U0126 (Calbiochem), sunitinib (LC
Labs), crizotinib (Selleck Chemicals, Houston, TX), and
ruxolitinib (LC Labs) were performed as described in the text.
All drugs were resuspended in DMSO prior to dilution in cell
culture media. Stimulation with recombinant CLCF1/CRLF1
heterodimeric ligand (R&D Systems, Minneapolis, MN) was
performed in serum-free RPMI-1640 media using 5 ng/mL
ligand concentration.
Antibodies
Phospho-specific antibodies for pEGFR
Y1068, pSTAT3
Y705,
pAKT
S7431, pERK
T202/Y204 and pS6
S235/S236 as well as the total
STAT3 and JAK2 antibodies were obtained from Cell Signaling
Technologies (Danvers, MA). The mouse monoclonal antibody to
tubulin was obtained from Sigma-Aldrich (St. Louis, MO). The
neutralizing mouse monoclonal to gp130 was obtained from R&D
Systems. The mouse monoclonal and rabbit polyclonal antibodies
used for the CLCF1 sandwich ELISA assay were obtained from
R&D Systems and Abcam (Cambridge, MA) respectively.
Immunoblotting
Cells grown under normal culture conditions were washed with
cold PBS and harvested on ice in cold pH 7.5 lysis buffer (20 mM
Tris-HCl , 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA,
2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate,
50 mM sodium fluoride, 1 mM Na3VO4, 1% Triton-X100,
1 mM DTT) supplemented with protease inhibitor cocktail
(Sigma-Aldrich, St. Louis, MO). Soluble protein from lysates was
quantified by Bradford assay (Bio-Rad, Hercules, CA). After
normalization of concentration, samples were diluted with
Laemmli buffer and denatured by boiling. Sample were then
separated on Tris-glycine polyacrylamide gels and transferred
overnight to nitrocellulose or nitrocellulose membranes in a wet
transfer apparatus (Hoefer, Holliston, MA). Membranes were
blocked in 3% non-fat dry milk in Tris-buffered saline/0.1%
Tween (TBS-T) and probed with primary antibodies overnight at
4uC. After washing in TBS-T buffer and incubation with a
horseradish peroxidase-coupled secondary antibody, membranes
were incubated in enhanced chemiluminescent reagent, exposed
to film and developed for signal using an X-omat processing
machine (Kodak, Rochester, NY).
Phospho-protein Array Analysis
Cell culture lysates obtained as indicated above were analyzed
using the Pathscan RTK Signaling Antibody Array Kit according
to the manufacturer recommended protocol (Cell Signaling,
Danvers, MA). Briefly, 250 mg of protein lysate from each cell
line was applied to a pre-blocked antibody array and incubated
overnight at 4uC with constant rocking. The arrays were washed
with PBS/0.05% Tween buffer and serially incubated for 1 hour
with the biotinylated detection antibody cocktail and DyLight-
680-conjugated streptavidin. After further washing, the arrays
were dried and imaged using a laser microarray scanner (Tecan,
Ma ¨nnedorf, Switzerland). Duplicate spot intensities were quanti-
fied from each array image using the QuantityOne software
package (BioRad, Hercules, CA).
Cyotokine Measurements
Conditioned media was collected from all seven cell lines
48 hours after plating in serum-free media. The samples were
submitted to Rules-Based Medicine (RBM, Austin, TX) for bead-
based immunodetection of 48 different cytokines including IL-6
(Inflammatory Cytokine Panel) (see Table S2 for complete list).
Replicate samples of conditioned media were concentrated with
10 kilodalton cutoff filtration vials (Millipore, Billerica, MA) and
assayed for CLCF1 using a sandwich ELISA protocol. Briefly, a
96-well plate was coated with rabbit polyclonal anti-CLCF1/
NNT1 (Abcam, diluted 1:500 in PBS) overnight at 4uC. After
washing 4 times with TBS/0.05% TritonX-100 (TBST), plates
were coated with 200 mL conditioned media. Antigen was allowed
to adhere overnight at at 4uC. Plates were then washed as above
and incubated for two hours with mouse monoclonal anti-CLCF1
(R&D Systems, diluted 1:500 in TBST/0.1% BSA). Plates were
washed again and incubated an additional hour with HRP-
conjugated goat anti-mouse secondary antibody. After a final
round of washing, plates were incubated with tetramethylbenzi-
dine (TMB) substrate (Cell Signaling) for 5 minutes, quenched
with 0.16 M sulfuric acid and measured for absorbance at 450 nm
using a multiplate reader (Molecular Devices, Sunnydale, CA).
Concentrations were normalized to a standard curve generated
with recombinant CLCF1 standard (R&D Systems) diluted in
serum-free media (see Fig S1B).
Quantitative RT-PCR
Total mRNA was harvested from cells grown under normal
conditions using the RNeasy miniprep kit according to manufac-
turer protocol (Qiagen, Valencia, CA). RNA was quantified by
UV-spectrophotometry and normalized for input of 1.0 mgo f
RNA into each cDNA synthesis reaction. Template cDNA was
synthesized using the iScript-Select kit and poly-dT primers (Bio-
Rad, Hercules, CA) according to standard manufacturer protocol
with a 90 minute extension phase to optimize synthesis of long
transcripts. The products of each cDNA synthesis reaction were
diluted 1:5 in Tris-EDTA buffer and used as template for
quantitative PCR. PCR reactions for each sample contained
10 mLo f2 6SYBR green reaction mix (Roche Applied Science,
Indianapolis, IN), 5 mL of template cDNA, 1.0 mM primers (IDT,
Coralville, IA) and sterile deionized water to a final 20 mL volume.
Reactions were performed on a 7500 Real Time thermocycler
(Applied Biosystems, Foster City, CA) according to standard
protocol with an added melting curve phase to ensure a single
PCR product was detected in each well. All reactions to quantify
IL-6 family ligand mRNAs were performed in triplicate and
normalized to averaged triplicate measurements of the house-
keeping gene RPL13A. Primers for these genes are indicated in
Table S4.
Immunofluorescent Staining and Microscopy
Cells were seeded to coverslips and allowed to adhere and grow
for 48 hours. Cells were then fixed with 4% paraformaldehyde
and permeabilized with 0.2% TritonX-100 in PBS. After blocking
with 5% normal goat serum in PBS, the coverslips were incubated
at 4uC overnight with a 1:100 dilution mouse monoclonal anti-
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PBS/0.02% TritonX-100, coverslips were incubated for one hour
with AlexaFluor-488 coupled anti-mouse secondary antibodies.
After a final round of washing, cells were co-stained with DAPI to
detect nuclei and coverslips were mounted on glass slides with anti-
fade gel mounting medium. Pictures were obtained using an LSM-
510 confocal microscope and LSM Image Browser software (Zeiss,
Stuttgart, Germany).
Production of Stable shRNA-Expressing Cell Lines
Stable knockdown cell lines were created by infecting cells with
pLK0.1-based lentiviral particles containing shRNAs targeted to
JAK2 (Sigma-Aldrich, St. Louis, MO) (JAK2-shRNA-1
[#TRCN0000003179], JAK2-shRNA-2 [#TRCN0000003180]).
. Forty-eight hours post-infection, cells were passaged and selected
with 2.0 mg/mL puromycin for an additional 72–96 hours prior to
analysis to eliminate uninfected cells. Stable lines were routinely
used for all assays within 1 week of selection to eliminate artifacts
caused by random selection for shRNA inactivation.
Tissue Acquisition and Tissue Microarray Construction
All lung tumor tissues analyzed in this study were retrospectively
obtained after prior approval of the Scottsdale Healthcare IRB
under Exemption 4 of Title 45 Code of Federal Regulations (CFR)
concerning retrospective study of existing data. Patient consent is
not required under this exemption and was not obtained for this
study, as Title 45 CFR Part 46 does not apply. The clinical
information associated with these specimens is not individually
identifiable, and was collected in such a manner that subjects
cannot be identified either directly or indirectly through identifiers
linked to the subjects. Tumor tissues were from patients diagnosed
between 2001 and 2007 with stage I–II NSCLC according to
AJCC 7
th edition criteria [45] who received care and follow-up at
Scottsdale Healthcare (SHC, Scottsdale, AZ). Tumor tissues were
collected from patients that underwent either surgical resection or
definitive radiation therapy and did not have a concomitant
diagnosis of malignancy within the preceding five years.
Pathological confirmation of NSCLC and histologic subtype was
rendered by a SHC board-certified pathologist at the time of
diagnosis. Confirmation of staging, collection and database
maintenance of clinical characteristics such as age at diagnosis,
gender, histology, stage, smoking history, and relapse-free and
overall survival was conducted by a board-certified medical
oncologist (GJW). The presence of baseline medical co-morbidities
including: diabetes, hypertension, cardiovascular disease (CAD),
lung disease [chronic obstructive pulmonary disease (COPD) or
emphysema], thrombotic event (deep vein thrombosis or pulmo-
nary embolism), peripheral vascular disease (PVD), and hyperlip-
idemia were also collected, where available. Hematoxylin and
eosin (H&E) stained slides of each tumor were reviewed by a
board-certified pathologist at TGen to identify representative
tumor regions in each sample. Two tissue cores (1 mm in
diameter) were taken from distinct regions of the primary tumor
from each case using a ATA100 tissue microarrayer (Chemicon,
Temecula, CA).
Immunohistochemistry
Freshly cut 5 micron sections from tissue microarray slides of
human lung tumors were deparaffinized with xylenes and
rehydrated through a series of graded ethanols. Subsequent
staining steps were performed on a Discovery XT automated
immunostainer (Ventana, Tucson, AZ). Antigen retrieval on all
tissues was performed by heating slides to 100uC in Tris-EDTA-
borate buffer, and then allowing them to cool gradually to room
temperature. Tissues were incubated with primary antibody (anti-
JAK2, 1:200; anti-STAT3, 1:200; or pSTAT3
Y705, 1:100) for
32 minutes at room temperature and then processed with the
UltraMAP biotin-free rabbit secondary antibody kit (Ventana).
After immunostaining, all tissues were counterstained with
hematoxylin and coverslipped using a Symphony automated
stainer (Ventana). Stained tissues were scored using the HSCORE
method, which is a composite of percent stained cells multiplied by
an intensity score (value of 0, 1, 2 or 3), allowing for a range of 0–
300 for each individual tissue [46]. For STAT3 and JAK2, a score
.100 was considered positive; for pSTAT3
Y705, a score .40 was
considered positive.
Statistical Analysis
All statistical analyses were performed using the R statistical
package (version 2.10.1). The relationship between two-class
discretized IHC values for individual antigens and histological
classes was assessed using Fisher’s exact test or the Chi-squared
test. Correlation between continuous variables was assessed using
the test for correlation between paired samples, employing
Pearson’s correlation coefficient. Survival analysis was performed
for right censored patient survival using Cox proportional hazards
regression models as implemented in the R survival package
(version 2.35–8). Models using continuous and two-class discre-
tized IHC values, as well as KRAS or EGFR mutation status as
predictors, were independently tested. Histological classes were
defined as adenocarcinoma (‘‘Adenocarcinoma’’, ‘‘mixed adeno’’,
‘‘Mucinous adenocarcinoma’’, ‘‘Papillary adenocarcinoma’’,
‘‘bronchioloalveolar carcinoma [BAC]’’), Squamous (‘‘Squa-
mous’’) or other (‘‘Large cell carcinoma’’, ‘‘NSCLC’’).
Cell Proliferation & Viability Analyses
Proliferation and survival curves were generated using the Cell
Titer Glo assay (Promega, Madison, WI). Luminescent values for
each condition were measured in quadruplicate wells and
normalized to media only control wells using an Envision
multiplate reader (PerkinElmer, Waltham, MA). Viability was
calculated as a percentage of untreated cells from the same line
24 hours post-treatment. Proliferation was calculated as a
percentage of untreated cells from the same line 72 hours after
drug treatment. Error bars represent the standard deviation of
triplicate values for each assay. Values were fit to survival and
proliferation curves using the Prism 5 software package (GraphPad
Software, La Jolla, CA).
Soft Agar Colony Formation Assays
Cell lines were suspended in RPMI-1640 media containing
0.35% agarose at 40uC at a density of 5,000 cells per 1.5 mL
media. This suspension was plated on top of a 1.5 mL plug of pre-
solidified RPMI-1640 media containing 0.5% agarose in a 6-well
plate. After allowing the cell suspension to solidify for overnight
under normal TC conditions, each agar plug was overlaid with
2 mL of RPMI-1640 media containing the indicated drug. Media
was changed three times per week on alternate days to maintain
adequate nutrient and drug concentrations until visible colonies
could be observed in the DMSO-treated wells. Upon the
completion of the assay, each agar plug was fixed and stained
overnight in a PBS solution containing 1% formaldehyde and
0.005% crystal violet. Agar plugs were destained by washing
thoroughly with PBS and imaged using a digital scanner (Hewlett-
Packard, Palo Alto, CA). Images were quantified for colony
number and size using the NIS Elements software package (Nikon,
Melville, NY). All assays were performed in triplicate. Error bars
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Statistical significance was determined by unpaired student t-test.
Xenograft Assays
Xenograft studies were performed at The Center for Transla-
tional Drug Development (TD2, Scottsdale, AZ) in compliance
with the Translational Genomics Research Institute Institutional
Animal Care and Use Committee (IACUC) under project number
TD2724. HCC827 cells were suspended in sterile, serum-free
RPMI-1640 growth medium at a concentration of 25610
6 cells/
mL. A volume of 0.2 mL (5610
6 cells) was inoculated into the
right flank of athymic nude mice, which were monitored for tumor
growth at the site of inoculation by palpation every other day until
tumors became palpable. Upon palpability, tumor size was
measured every other day using calipers and the tumor volume
was calculated using the formula (length 6width
2 60.52). When
mean tumor volume reached 100 mm
3, the mice were random-
ized into two different treatment arms with six mice per arm. A
stock solution of ruxolitinib was prepared in ethanol and
suspended in vehicle (0.5% hydroxypropyl-methylcellulose/0.2%
Tween 80 in PBS) prior to treatment. Mice were treated daily by
oral gavage with vehicle or ruxolitinib (50 mg/kg). The primary
endpoints for the study were one month (30 days) of drug
treatment or achievement of 500 mm
3 volume.
Supporting Information
Figure S1 Quantification of IL-6 Family Ligand Expres-
sion. A, Quantitative RT-PCR was performed on cDNA samples
obtained from each of the seven indicated NSCLC cell lines.
Percent expression was normalized to the housekeeping gene
RPL13A. Error bars represent standard deviations of triplicate
measurements. B, Sandwich ELISA standard curve of CLCF1
ligand determined using a two-fold serial dilution of recombinant
CLCF1 in serum-free media. Absorbance at 450 nM is plotted
against the concentration of CLCLF1. C, Secreted CLCF1 levels
were measured in 48 hour conditioned media samples by sandwich
ELISA. Values are duplicate measurements from each cell line. nd,
not detected. D, The indicated cell lines were retained in basal
media containing 10% fetal bovine serum (basal), or serum-starved
for one hour prior to treatment +/2 recombinant CLCF1/CRLF1
(5 ng/mL). The expression level and phosphorylation status of
STAT3 (pSTAT3
Y705) were evaluated by immunoblot, along with
b-actin as a loading control. The neuroblastoma cell line SH-SY5Y
was included as a positive control to demonstrate bioactivity of the
recombinant CLCF1/CRLF1 ligand.
(TIF)
Figure S2 JAK2 inhibition with ruxolitinib does not
affect proliferation of NSCLC lines in two-dimensional
tissue culture. A, NCI-H358 cells were treated in quadruplicate
with a 3-fold serial dilution of the MEK1/2 inhibitor U0126
(range, 0–30 mM) +/2 1.0 mM ruxolitinib. Cell number was
measured at 72 hours after treatment and normalized to untreated
controls. Averaged values for each condition are shown as a
percentage of vehicle-treated (DMSO) cells. Error bars indicate
standard deviations of the four replicate values. B, HCC4006 cells
were treated in quadruplicate for 72 hours with a 3-fold serial
dilution of the EGFR inhibitor erlotinib (range, 0–1.0 mM) +/2
1.0 mM ruxolitinib. Cell number and percent proliferation were
evaluated as in A. C, NCI-H1703 cells were treated in
quadruplicate for 24 hours with a 3-fold serial dilution of the
PDGFR inhibitor sunitinib (range, 0–100 mM) +/2 1.0 mM
ruxolitinib. Cell number and percent proliferation were evaluated
as in A.
(TIF)
Table S1 NSCLC Cell Line Mutational Profile. Mutation-
al status of common oncogenes and tumor suppressors in the seven
NSCLC lines used for this study were obtained from the
Catalogue of Somatic Mutations in Cancer (COSMIC) database
[47].
(PDF)
Table S2 NSCLC Cell Line Cytokine Measurements.
Duplicate measurements of 46 different inflammatory cytokines in
conditioned media from the seven NSCLC cell lines used in this
study was performed using a commercial bead-based immunoas-
say (Human InflammationMAP_v1.0). For each cytokine, the least
detectable dose (LDD) was determined as the mean +3 standard
deviations of 20 blank readings. Results below the LDD are more
variable than results above the LDD. The value ,LOW. reflects
samples not measurable on the standard curve.
(PDF)
Table S3 Patient disease characteristics and outcome
statistics. Key clinical, histological and treatment features, as
well as outcome statistics, of the patient population represented on
our tissue microarray are indicated. Mutational status for KRAS
and EGFR are also shown for this population.
(PDF)
Table S4 Primers for IL-6 Family q-RT-PCR. Oligonu-
cleotide sequences of each primer pair (forward and reverse, 59-to-
39) used in quantitative RT-PCR detection of IL-6 family ligands
are shown. Each pair was validated to produce a single PCR
fragment of the expected length by gel electrophoresis.
(PDF)
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